A new strategy to build caged-compounds is presented. The approach is based on heterolytic photocleavage of a metal-ligand bond in a coordination compound. A ruthenium polypyridine complex, containing the neurocompound 4-amino pyridine (4AP) is used as the core of the phototrigger. The biomolecule is released by irradiation with visible light (>480 nm). The liberated 4AP promotes the activation of a leech neuron by means of blocking its K+ channels. The syntesis, characterization, and the inherent advantages of this method are discussed.
We report the synthesis, characterization, and spectroscopic properties of a family of trinuclear cyano-bridged mixed-valent compounds, trans-[Ru(II)L(4)[NCFe(III)(CN)(5)](2)](4-), trans-[Ru(II)L(4)[CNFe(III)(CN)(5)](2)](4-), and cis-[Ru(II)(bpy)(2)[NCFe(III)(CN)(5)](2)](4-) (L = pyridine, 4-tert-butylpyridine, and 4-methoxypyridine). Tetraphenylphosphonium salts of complexes trans-[Ru(II)L(4)[NCFe(III)(CN)(5)](2)](4-) (L = pyridine and 4-tert-butylpyridine) crystallize in the space groups C2 and P2(1)/c, respectively, and show a linear arrangement of the metal units and an almost completely eclipsed configuration of the equatorial ligands. An intense band (epsilon approximately 2000-9000 M(-1) cm(-1)) is observed for all of the compounds in the NIR region of the spectrum, not present in the separated building blocks, and strongly solvent dependent. We assign it as a metal-to-metal charge transfer (MMCT) from the Ru(II) to the terminal Fe(III) moieties in the context of a simplified three-center model. The electrochemistry measurements reveal a splitting of the redox waves for the reduction of the iron centers for some of the complexes with a trans configuration between the metal units, ranging from 100 to 260 mV, depending on the substituting pyridine ligand and the solvent, suggesting long-range metal-metal interactions. These interactions are rationalized in terms of the energy matching between the pi-symmetry orbitals of the metals and the cyanide bridge. The one- and two-electron reduced species derived from compounds trans-[Ru(II)L(4)[NCFe(III)(CN)(5)](2)](4-,5-,6-) were characterized in methanolic solution. The mixed-valent Fe(II)-Ru(II)-Fe(III) system exhibits an intense red shifted band in the NIR region of the spectrum, arising from the superposition of MMCT bands from the central Ru(II) to the terminal Fe(III) fragments and from the 1 nm distant Fe(II) to Fe(III) centers.
In this article, we report the structural, spectroscopic, and electrochemical properties of the cyanide-bridged complex salts trans-[(NC)Ru(II)(L)4(μ-CN)Ru(II)(py)4Cl]PF6 and trans-[Ru(II)(L)4{(μ-CN)Ru(II)(py)4Cl}2](PF6)2 (L = pyridine or 4-methoxypyridine). The mixed-valence forms of these compounds show a variety of metal-to-metal charge-transfer bands, including one arising from charge transfer between the remote ruthenium units. The latter is more intense when L = 4-methoxypyridine and points to the role of the bridging ruthenium unit in promoting mixing between the dπ orbitals of the terminal fragments.
The NIR and IR spectroscopic properties of the cyanide-bridged complex, trans-[Ru(dmap)4 {(μ-CN)Ru(py)4 Cl}2 ](3+) (py=pyridine, dmap=4-dimethylaminopyridine) provide strong evidence that this trimetallic ion behaves as a Class III mixed-valence species, the first example reported of a cyanide-bridged system. This has been accomplished by tuning the energy of the fragments in the trimetallic complex to compensate for the intrinsic asymmetry of the cyanide bridge. Moreover, (TD)DFT calculations accurately predict the spectra of the trans-[Ru(dmap)4 {(μ-CN)Ru(py)4 Cl}2 ](3+) ion and confirms its delocalized nature.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.